BioGraphene Signs Collaboration Agreement with Dr. Paulina Ordonez for BGN-112’s Pharmacodynamic Study

2022
Written By BioGraphene
 

BioGraphene Inc. announced that the company entered into a Collaboration Agreement with Dr. Paulina Ordonez, an assistant adjunct professor of pediatrics at UC San Diego School of Medicine and a member of the Division of Gastroenterology, Hepatology & Nutrition at Rady Children's Hospital-San Diego for BGN-112’s pharmacodynamic study.

This study will validate BGN-112’s role in alleviating mitochondrial dysfunction in Niemann-Pick Disease Type C and other diseases.

BioGraphene
Previous

BioGraphene Signs Patent License Agreement with Seoul National University and Johns Hopkins University
Next

BioGraphene Signs Collaborative Research Agreement with Dong-A University for the Efficacy Study of Graphene Quantum Dots in ALS